Department of Clinical Neurosciences, Foothills Medical Center, University of Calgary, Foothills Medical Centre, 1403 29th St NW, Calgary, AB T2N 2T9, Canada.
Department of Diagnostic Imaging, Foothills Medical Center, University of Calgary, Calgary, AB, Canada.
J Neuroradiol. 2022 Mar;49(2):157-163. doi: 10.1016/j.neurad.2021.08.001. Epub 2021 Sep 20.
Patients with acute ischemic stroke due to medium vessel occlusion (MeVO) make up a substantial part of the acute stroke population, though guidelines currently do not recommend endovascular treatment (EVT) for them. A growing body of evidence suggests that EVT is effective in MeVOs, including observational data but no randomized studies. We aimed to explore willingness of physicians worldwide to randomize MeVO stroke patients into a hypothetical trial comparing EVT in addition to best medical management versus best medical management only.
In an international cross-sectional survey among stroke physicians, participants were presented with 4 cases of primary MeVOs (6 scenarios each). Each subsequent scenario changed one key patient characteristic compared to the previous one, and asked survey participants whether they would be willing to randomize the described patient. Overall, physician- and scenario-specific decision rates were calculated. Multivariable logistic regression with clustering by respondent was performed to assess factors influencing the decision to randomize.
Overall, 366 participants (56 women) from 44 countries provided 8784 answers to 24 MeVO case scenarios. The majority of responses (78.3%) were in favor of randomizing. Most physicians were willing to accept patients transferred for EVT from a primary center (82%) and the majority of these (76.5%) were willing to randomize these patients after transfer. Patient age > 65 years, A3 occlusion, small core volume, and patient intravenous alteplase eligibility significantly influenced the physician's decision to randomize (adjOR 1.24, 95%CI 1.13-1.36; adjOR 1.17, 95%CI 1.01-1.34; adjOR 0.98, 95%CI 0.97-0.99 and adjOR 1.38, 95%CI 1.21-1.57, respectively).
Most physicians in this survey were willing to randomize acute MeVO stroke patients irrespective of patient characteristics into a trial comparing EVT in addition to best medical management versus best medical management only, suggesting there is clinical equipoise.
由于中等大小血管闭塞(MeVO)导致的急性缺血性脑卒中患者在急性脑卒中患者中占有相当大的比例,但目前的指南并不推荐对其进行血管内治疗(EVT)。越来越多的证据表明,EVT 对 MeVOs 有效,包括观察性数据,但没有随机研究。我们旨在探索全球医生对将急性 MeVO 脑卒中患者随机分配到一项假设性试验的意愿,该试验比较了 EVT 联合最佳药物治疗与单纯最佳药物治疗。
在一项针对脑卒中医生的国际横断面调查中,参与者对 4 例原发性 MeVO(每个病例 6 种情况)进行了评估。每种情况下都改变了与前一种情况相比的一个关键患者特征,并询问调查参与者是否愿意对所描述的患者进行随机分组。总体而言,计算了医生和方案特异性决策率。采用多元逻辑回归并按应答者进行聚类,以评估影响随机分组决策的因素。
共有来自 44 个国家的 366 名(56 名女性)参与者对 24 例 MeVO 病例场景提供了 8784 个答案。大多数情况下(78.3%)的回答倾向于随机分组。大多数医生愿意接受从初级中心转来接受 EVT 的患者(82%),其中大多数(76.5%)愿意在转来后对这些患者进行随机分组。患者年龄>65 岁、A3 闭塞、小核心体积和患者静脉内阿替普酶适应证显著影响医生的随机分组决策(调整后比值比 1.24,95%CI 1.13-1.36;调整后比值比 1.17,95%CI 1.01-1.34;调整后比值比 0.98,95%CI 0.97-0.99 和调整后比值比 1.38,95%CI 1.21-1.57)。
在这项调查中,大多数医生愿意将急性 MeVO 脑卒中患者随机分组,无论患者特征如何,纳入一项比较 EVT 联合最佳药物治疗与单纯最佳药物治疗的试验,表明存在临床均衡。